Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Alzheimer's Imaging Consortium
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Journal of Alzheimer'S Disease : JAD
|
November 10, 2018
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
H Robert Brashear, Nzeera Ketter, Jennifer Bogert, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Martine Meyer, David Henley, Jennifer Bogert, et al.
Journal of Alzheimer'S Disease : JAD
|
March 9, 2017
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients
Nzeera Ketter, H Robert Brashear, Jennifer Bogert, et al.
Journal of Affective Disorders
|
June 16, 2021
A randomized, multicenter, crossover psychometric evaluation study of an iPad-administered cognitive test battery in participants with major depressive disorder who responded to treatment with oral antidepressants
Jennifer Bogert, Hany Rofael, Kenneth Mosca, et al.
Alzheimer'S Research & Therapy
|
May 22, 2016
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
Bianca Van Broeck, Maarten Timmers, Steven Ramael, et al.
Alzheimer'S Research & Therapy
|
May 16, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, et al.
Neurobiology of Aging
|
May 6, 2019
Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease
Maarten Timmers, Ina Tesseur, Jennifer Bogert, et al.
Journal of Clinical Pharmacology
|
March 6, 2018
Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis
Maarten Timmers, Vikash Sinha, Borje Darpo, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 23, 2025
Alzheimer's Imaging Consortium
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Ziad S Saad, Ritobrato Datta, Maggie Fedgchin, et al.
Journal of Alzheimer'S Disease : JAD
|
November 10, 2018
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
H Robert Brashear, Nzeera Ketter, Jennifer Bogert, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Martine Meyer, David Henley, Jennifer Bogert, et al.
Journal of Alzheimer'S Disease : JAD
|
March 9, 2017
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients
Nzeera Ketter, H Robert Brashear, Jennifer Bogert, et al.
Journal of Affective Disorders
|
June 16, 2021
A randomized, multicenter, crossover psychometric evaluation study of an iPad-administered cognitive test battery in participants with major depressive disorder who responded to treatment with oral antidepressants
Jennifer Bogert, Hany Rofael, Kenneth Mosca, et al.
Alzheimer'S Research & Therapy
|
May 22, 2016
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
Bianca Van Broeck, Maarten Timmers, Steven Ramael, et al.
Alzheimer'S Research & Therapy
|
May 16, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, et al.
Neurobiology of Aging
|
May 6, 2019
Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease
Maarten Timmers, Ina Tesseur, Jennifer Bogert, et al.
Journal of Clinical Pharmacology
|
March 6, 2018
Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis
Maarten Timmers, Vikash Sinha, Borje Darpo, et al.
Page
of 2